Introduction
Xarelto (Rivaroxaban) is a relatively new anti-coagulant (blood thinner). The Food & Drug Administration (FDA) initially approved Xarelto in July 2011 for use following knee and hip surgery to reduce the risks of deep vein thrombosis (DVT). In November 2011, the FDA approved the drug for additional use as an anti-coagulant in individuals with non-valvular atrial fibrillation.
History of the Case
In November 2012, the FDA extended approval to patients with DVT and pulmonary embolism as well as for long-term treatment to prevent recurrence. Xarelto users sued Johnson & Johnson, Janssen Pharmaceuticals and Bayer Corporation, claiming they suffered from internal bleeding, wound leakage and infections after taking the popular anti-clotting drug. The drug’s makers won six trials but agreed to settle thousands of lawsuits for $775 million in March 2019.
Injuries Related to Product
- Uncontrollable Bleeding
- Wound Infections
- Hepatitis
- Stevens-Johns Syndrome (SJS)
